RESUMO
Background. Studies of platelet aggregation (PA) in essential thrombocythemia (ET) reported contrasting results, likely due to differences in analytical conditions.Objective. We investigated platelet aggregation using different techniques and analytical conditions.Patients and Methods. PA was studied by light-transmission aggregometry (LTA) in platelet-rich plasma (PRP) and impedance aggregometry in PRP and whole blood (WB). ADP, collagen, thrombin receptor activating peptide (TRAP-14) and adrenaline were used as agonists. Since ET patients (n = 41) were on treatment with aspirin (100 mg/d), healthy controls (n = 29) were given aspirin (100 mg/d) for 5 days before testing: therefore, thromboxane A2-independent PA was tested in all subjects. Blood samples were collected in citrate (C) [low Ca2+] or lepirudin (L) [physiological Ca2+]; platelet count was adjusted to 250 x 109/L in a set of C-PRP (adjusted C-PRP) and left unmodified in the other samples.Results. Results of PA in 17 ET patients who were poor responders to aspirin (high serum thromboxane B2 levels) were not included in the analysis. With LTA, PA in ET was lower than in controls in adjusted C-PRP and normal in native C-PRP and L-PRP. With impedance aggregometry, PA in L-PRP and L-WB tended to be higher in ET than in controls. Platelet serotonin and ADP contents were reduced in ET. The percentages of circulating platelets expressing P-selectin and platelet-leukocyte hetero-aggregates were higher in ET.Conclusions. Analytical conditions dramatically affect in vitro PA of ET patients, which appears defective under the least physiological conditions and normal/supranormal under conditions that are closer to the physiological.
Assuntos
Plaquetas/fisiologia , Testes de Função Plaquetária/métodos , Plasma Rico em Plaquetas , Trombocitemia Essencial/sangue , Nucleotídeos de Adenina/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Aspirina , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Ácido Cítrico/farmacologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Selectina-P/sangue , Agregação Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacologia , Contagem de Plaquetas , Plasma Rico em Plaquetas/efeitos dos fármacos , Serotonina/sangue , Trombocitemia Essencial/tratamento farmacológico , Trombocitemia Essencial/patologia , Adulto JovemAssuntos
Plaquetas/enzimologia , Fosfolipases A2 do Grupo IV/metabolismo , Ácido Araquidônico/metabolismo , Estabilidade Enzimática , Genótipo , Fosfolipases A2 do Grupo IV/deficiência , Fosfolipases A2 do Grupo IV/genética , Células HEK293 , Humanos , Mutação , Fenótipo , Proteínas Recombinantes de Fusão/metabolismo , TransfecçãoRESUMO
Defects of the platelet P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP) are associated with increased bleeding risk. The study of molecular abnormalities associated with inherited qualitative defects of the P2Y12R protein is useful to unravel structure-function relationships of the receptor. We describe the case of 2 brothers, sons of first cousins, with lifelong history of abnormal bleeding, associated with dysfunctional P2Y12R and a previously undescribed missense mutation in the encoding gene. ADP (4-20 µM)-induced aggregation of patients' platelets was markedly reduced and rapidly reversible. Other agonists induced borderline-normal aggregation. Inhibition of vasodilator-stimulated phosphoprotein phosphorylation and prostaglandin E1-induced increase in cyclic adenosine monophosphate (cAMP) by ADP was impaired, whereas inhibition of cAMP increase by epinephrine was normal. [(3)H]PSB-0413, a selective P2Y12R antagonist, bound to a normal number of binding sites; however, its affinity, and that of the agonists ADP and 2-methylthio-adenosine-5'-diphosphate, was reduced. Patients' DNA showed a homozygous c.847T>A substitution that changed the codon for His-187 to Gln (p.His187Gln). Crystallographic data and molecular modeling studies indicated that His187 in transmembrane 5 is important for agonist and nucleotide antagonist binding and located in a region undergoing conformational changes. These studies delineate a region of P2Y12R required for normal function after ADP binding.
Assuntos
Transtornos Plaquetários/genética , Plaquetas/patologia , Transtornos Hemorrágicos/genética , Mutação Puntual , Receptores Purinérgicos P2Y12/genética , Difosfato de Adenosina/metabolismo , Monofosfato de Adenosina/análogos & derivados , Monofosfato de Adenosina/metabolismo , Transtornos Plaquetários/metabolismo , Transtornos Plaquetários/patologia , Plaquetas/metabolismo , AMP Cíclico/metabolismo , Transtornos Hemorrágicos/metabolismo , Transtornos Hemorrágicos/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Simulação de Acoplamento Molecular , Linhagem , Agregação Plaquetária , Receptores Purinérgicos P2Y12/metabolismo , Tionucleosídeos/metabolismoRESUMO
A few naturally occurring N(6)-substituted adenosine derivatives (cytokinin ribosides) were investigated as inhibitors of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 µM). A docking study suggests that anti-aggregation activity of these compounds could involve an interaction with the P2Y12 receptor binding site.
Assuntos
Plaquetas/citologia , Plaquetas/metabolismo , Citocininas/metabolismo , Inibidores da Agregação Plaquetária/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Receptores Purinérgicos P2Y12/metabolismo , Ribonucleosídeos/metabolismo , Adenosina/química , Adenosina/metabolismo , Difosfato de Adenosina/metabolismo , Citocininas/química , Humanos , Técnicas In Vitro , Reguladores de Crescimento de Plantas/química , Reguladores de Crescimento de Plantas/metabolismo , Agonistas do Receptor Purinérgico P1/química , Agonistas do Receptor Purinérgico P1/metabolismo , Ribonucleosídeos/químicaRESUMO
INTRODUCTION: This study aimed to characterize the in vitro effect of EV-077, a compound that antagonises the binding of prostanoids and isoprostanes to the thromboxane receptor (TP) and inhibits the thromboxane synthase (TS), on platelet aggregation of patients with type-2 diabetes and coronary artery disease (CAD) on chronic aspirin treatment. The effect of EV-077 on 8-iso-PGE(2)-mediated TP receptor contraction of human arteries was also investigated. MATERIALS AND METHODS: Fifty-two type-2 diabetics with CAD on chronic aspirin (100 mg) treatment were studied. Arachidonic acid-induced platelet aggregation was measured by impedance aggregometry in platelet-rich plasma (PRP) and whole blood anticoagulated with hirudin, and by light transmission aggregometry in citrate-anticoagulated PRP following 10-min in vitro exposure to EV-077 (100 nmol/l) or control. The effect of EV-077 was measured on isometric contraction of 24 human umbilical arteries induced by isoprostane 8-iso-PGE(2). RESULTS: Arachidonic acid (1 mmol/l) induced substantial aggregation in hirudin-anticoagulated whole blood (63 ± 4 AU), which was significantly reduced by in vitro exposure to EV-077 (38 ± 3 AU, P<0.001). Virtually no arachidonic acid-induced aggregation in citrate-anticoagulated or hirudin-anticoagulated PRP was observed. EV-077 potently, competitively and reversibly inhibited TP mediated contraction of umbilical arteries by 8-iso-PGE(2) (P<0.01). CONCLUSIONS: Aspirin did not completely inhibit arachidonic acid-induced platelet aggregation in whole blood from type-2 diabetics with CAD. This aggregation is likely induced by prostanoids and/or isoprostanes produced by leukocytes, because it was significantly reduced by EV-077. The TP receptor-mediated contraction of human arteries induced by isoprostane 8-iso-PGE(2) was effectively inhibited by EV-077.
Assuntos
Aspirina/administração & dosagem , Doença da Artéria Coronariana/sangue , Doença da Artéria Coronariana/tratamento farmacológico , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/tratamento farmacológico , Agregação Plaquetária/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Anticoagulantes/administração & dosagem , Ácido Araquidônico/farmacologia , Dinoprostona/análogos & derivados , Dinoprostona/farmacologia , Feminino , Hirudinas/farmacologia , Humanos , Isoprostanos/farmacologia , Masculino , Pessoa de Meia-Idade , Inibidores da Agregação Plaquetária/administração & dosagem , Artérias Umbilicais/efeitos dos fármacos , Resistência Vascular/efeitos dos fármacosRESUMO
BACKGROUND: Inflammation is a key feature of HIV infection and is correlated with long-term negative cardiovascular outcomes. Therapy-induced increases in CD4(+) cell counts can control inflammation, as shown by decreases of coagulation and inflammation markers during efficacious therapy. Maraviroc, a CCR5-antagonist, has resulted in larger increases in CD4(+) counts both in naïve and experienced subjects compared to traditional antiretroviral therapy. OBJECTIVES AND METHODS: To examine if a member of the protein C anticoagulant and anti-inflammatory pathway, and marker of coagulation and inflammation, the soluble endothelial protein C receptor, is modified by infection and therapy-related variables in patients treated with Maraviroc. Endothelial protein C receptor, together with other established markers of inflammation and coagulation (CRP, IL-6, D-dimer and soluble thrombomodulin) was studied in 43 patients on traditional antiretroviral therapy and in 45 on Maraviroc during 48 weeks of follow-up. RESULTS: Soluble endothelial protein C receptor was the only marker that could discriminate at least partially between patients with a good response to Maraviroc and patients who did not respond with an adequate increase in CD4(+) cell counts (more than 500 cells/µL by week 48). CONCLUSIONS: Elevated levels of soluble endothelial protein C receptor, a sensitive marker of endothelial damage, indicated a low level of inflammation and coagulation activation in Maraviroc treated patients not picked up by other widely used markers. Persistent elevated levels of this marker at 48 weeks from beginning of treatment with Maraviroc were related to a poor increase in CD4(+) cells.
Assuntos
Antígenos CD/imunologia , Antagonistas dos Receptores CCR5/administração & dosagem , Cicloexanos/administração & dosagem , Infecções por HIV/tratamento farmacológico , Infecções por HIV/imunologia , Receptores de Superfície Celular/imunologia , Triazóis/administração & dosagem , Adulto , Idoso , Antígenos CD/sangue , Biomarcadores/sangue , Coagulação Sanguínea/efeitos dos fármacos , Contagem de Linfócito CD4 , Receptor de Proteína C Endotelial , Endotélio Vascular/imunologia , Endotélio Vascular/lesões , Endotélio Vascular/metabolismo , Feminino , Seguimentos , Infecções por HIV/sangue , Humanos , Masculino , Maraviroc , Pessoa de Meia-Idade , Receptores de Superfície Celular/sangueAssuntos
Fator V/genética , Mutação , Protrombina/genética , Adulto , Estudos de Coortes , Feminino , Heterozigoto , Humanos , Masculino , Países Baixos , Inanição/mortalidade , Sobrevida , Trombofilia/genética , Fatores de Tempo , Resultado do TratamentoRESUMO
P2Y(12) plays an important role in platelet aggregation, which makes it an interesting target for antithrombotic agents. Compounds that antagonize P2Y(12) include the active metabolites of thienopyridines and molecules that are structurally related to ATP, which is an antagonist of P2Y(12). During the last few years, our group has been working on the development of P2Y(12) receptors antagonists that are based on an extremely simple chemical structure, the 6-amino-2-mercapto-3H-pyrimidin-4-one, variously substituted at the sulfur and oxygen functions. This nucleus represents the simplified combination of two known P2Y(12) antagonists: the active metabolite of the thienopyridines and ATP derivatives. The effects of the synthesized compounds were tested on ADP-induced human platelet aggregation, using light transmission aggregometry. None of the tested compounds induced platelet aggregation, while some of them, at concentration of 10(-4)M, partially inhibited platelet aggregation induced by ADP 10(-6)M. The most potent compound, 6b, antagonized the inhibitory effect of 2-methylthio-ADP on the forskolin-induced accumulation of cyclic-AMP in CHO FlpIN cells expressing recombinant human P2Y(12)-receptors. In addition, none of the tested compounds, including 6b, interfered with ligand binding to P1 receptors. Our results suggest that some of the synthesized compounds are specific antagonists of P2 receptors, and in particular of P2Y(12) and suggest that further development of this structurally new series of compounds as P2Y(12) receptors antagonists is recommended.
Assuntos
Agregação Plaquetária/efeitos dos fármacos , Antagonistas do Receptor Purinérgico P2 , Pirimidinonas/química , Pirimidinonas/farmacologia , Receptores Purinérgicos P2/metabolismo , Compostos de Sulfidrila/química , Compostos de Sulfidrila/farmacologia , Animais , Células CHO , Clonagem Molecular , Cricetinae , Cricetulus , AMP Cíclico/metabolismo , Humanos , Estrutura Molecular , Testes de Função Plaquetária , Ligação Proteica , Receptores Purinérgicos P1/genética , Receptores Purinérgicos P1/metabolismo , Receptores Purinérgicos P2/genética , Receptores Purinérgicos P2Y12 , Proteínas Recombinantes/antagonistas & inibidores , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Relação Estrutura-AtividadeRESUMO
Human chromosomes are capped by telomeres, which consist of tandem repeats of DNA and associated proteins. The length of the telomeres is reduced with increasing cell divisions except when the enzyme telomerase is active, as in stem cells and germ cells. Telomere dysfunction has been associated with development of age-related pathologies, including cancer, cardiovascular disease, Alzheimer's disease, and Parkinson's disease. DNA damage in the telomeric region causes attrition of telomeres. Because folate provides precursors for nucleotide synthesis and thus affects the integrity of DNA, including that of the telomeric region, folate status has the potential to influence telomere length. Telomere length is epigenetically regulated by DNA methylation, which in turn could be modulated by folate status. In this study, we determined whether folate status and the 677C > T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene are associated with the telomere length of peripheral blood mononuclear cells in healthy men. The results of our study showed that plasma concentration of folate was associated with telomere length of peripheral blood mononuclear cells in a nonlinear manner. When plasma folate concentration was above the median, there was a positive relationship between folate and telomere length. In contrast, there was an inverse relationship between folate and telomere length when plasma folate concentration was below the median. The MTHFR 677C > T polymorphism was weakly associated (P = 0.065) with increased telomere length at below-median folate status. We propose that folate status influences telomere length by affecting DNA integrity and the epigenetic regulation of telomere length through DNA methylation.
Assuntos
Ácido Fólico/metabolismo , Leucócitos Mononucleares/citologia , Polimorfismo de Nucleotídeo Único , Telômero/ultraestrutura , Senescência Celular , DNA/genética , Ácido Fólico/sangue , Genótipo , Homocisteína/sangue , Humanos , Masculino , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Reação em Cadeia da Polimerase , RNA/genética , Vitamina B 12/sangue , Globinas beta/genéticaRESUMO
We describe a procedure for quantification of vitamin K(1) in human plasma by HPLC. Samples, enriched with a vitamin K derivative as internal standard, were deproteinized, purified on polymeric RP-SPE cartridges and injected into HPLC equipped with a post-column on-line zinc metal reactor and a fluorometric detector. Median level in blood donors (n=87) was 1.967 nmol/L (0.93-4.01, 5th-95th percentiles), with a significant correlation between plasma levels and age (r=0.276, p=0.00958) and a lower (not significant) value in women than in men. This method, easy-to-handle and with a high throughput, can be used to identify covert states of vitamin K intake deficiency in patients thus at risk of alterations in blood clotting or bone mineralization.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Extração em Fase Sólida/métodos , Vitamina K 1/sangue , Adulto , Idoso , Análise de Variância , Feminino , Fluorescência , Humanos , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Padrões de ReferênciaAssuntos
Mutação , Proteína S/genética , Proteína S/metabolismo , Trombina/metabolismo , Trombose Venosa/sangue , Trombose Venosa/genética , Adulto , Western Blotting , Caspases/metabolismo , Linhagem Celular , Éxons , Citometria de Fluxo , Humanos , Íntrons , Masculino , Proteína S/química , Trombose Venosa/diagnósticoRESUMO
Activated protein C (APC) has potent anticoagulant and anti-inflammatory properties that are mediated in part by its interactions with its cofactor protein S and the endothelial cell protein C receptor (EPCR). The protein C/APC Gla domain is implicated in both interactions. We sought to identify how the protein C Gla domain enables specific protein-protein interactions in addition to its conserved role in phospholipid binding. The human prothrombin Gla domain, which cannot bind EPCR or support protein S cofactor activity, has 22/45 residues that are not shared with the human protein C Gla domain. We hypothesized that the unique protein C/APC Gla domain residues were responsible for mediating the specific interactions. To assess this, we generated 13 recombinant protein C/APC variants incorporating the prothrombin residue substitutions. Despite anticoagulant activity similar to wild-type APC in the absence of protein S, APC variants APC(PT33-39) (N33S/V34S/D35T/D36A/L38D/A39V) and APC(PT36/38/39) (D36A/L38D/A39V) were not stimulated by protein S, whereas APC(PT35/36) (D35T/D36A) exhibited reduced protein S sensitivity. Moreover, PC(PT8/10) (L8V/H10K) displayed negligible EPCR affinity, despite normal binding to anionic phospholipid vesicles and factor Va proteolysis in the presence and absence of protein S. A single residue variant, PC(PT8), also failed to bind EPCR. Factor VIIa, which also possesses Leu-8, bound soluble EPCR with similar affinity to wild-type protein C, collectively confirming Leu-8 as the critical residue for EPCR recognition. These results reveal the specific Gla domain residues responsible for mediating protein C/APC molecular recognition with both its cofactor and receptor and further illustrate the multifunctional potential of Gla domains.
Assuntos
Proteína C/química , Sequência de Aminoácidos , Anti-Inflamatórios/farmacologia , Endotélio Vascular/citologia , Fator VII/metabolismo , Fator Va/química , Variação Genética , Humanos , Dados de Sequência Molecular , Fosfolipídeos/química , Proteína S/química , Estrutura Terciária de Proteína , Protrombina/química , Homologia de Sequência de AminoácidosAssuntos
Polimorfismo Genético , Serpinas/genética , Trombose Venosa/genética , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Feminino , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Prevalência , Risco , Tromboembolia/genéticaRESUMO
The Protein S Italian Team (PROSIT) enrolled 79 protein S (PS) deficient families and found 38 PROS1 variations (19 novel) in 53 probands. Of these, 23 variants were selected for expression in'vitro, to evaluate their role as possible causative variants. Transient expression showed high secretion levels (>75%) for three variants, which were considered neutral. Seven missense and five nonsense variants showed low (Assuntos
Heterogeneidade Genética
, Deficiência de Proteína S/genética
, Proteína S/genética
, Trombofilia/genética
, Códon sem Sentido
, Análise Mutacional de DNA
, Fator Va/análise
, Humanos
, Itália/epidemiologia
, Mutação de Sentido Incorreto
, Modelos de Riscos Proporcionais
, Deficiência de Proteína S/complicações
, Deficiência de Proteína S/epidemiologia
, Embolia Pulmonar/epidemiologia
, Embolia Pulmonar/etiologia
, Sítios de Splice de RNA/genética
, Medição de Risco
, Trombofilia/etiologia
, Tromboflebite/epidemiologia
, Tromboflebite/etiologia
, Trombose Venosa/epidemiologia
, Trombose Venosa/etiologia